Key result
Saroglitazar lacks reported quantitative data on dyslipidemia and liver enzymes.
Why the study?
Does saroglitazar improve dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease?
Observational
Does saroglitazar improve dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease?
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bhaduri et al. (2025) conducted an observational in Type 2 diabetes, MASLD, and Stage 3 chronic kidney disease. Saroglitazar was evaluated on Dyslipidaemia and liver enzymes. Saroglitazar effectiveness and safety in managing dyslipidaemia and liver enzymes were not quantitatively reported in the provided abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: